Clinical Trial Update: The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating the addition of metformin to SGLT2 inhibitors in patients with type 2 diabetes and heart failure with preserved ejection f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Type 2 Diabetes Mellitus

Drugs mentioned

• SGLT2 inhibitors (SGLT2 inhibitor)
• metformin (metformin)

Snippet

Sponsor: October University for Modern Sciences and Arts | Conditions: Heart Failure With Preserved Ejection Fraction, Diabete Type 2 | Phase 2, Phase 3 | Status: UNKNOWN